The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
Featured:
Anita RijneveldDuring the EHA 2022 Congress, the ALL Hub was pleased to speak to Anita Rijneveld, Erasmus MC, Rotterdam, NL. We asked, Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
Rijneveld begins by stating the importance of MRD negativity in improving outcomes of ALL. Rijneveld then discusses the results of her phase II study, in which patients were given blinatumomab after consolidation therapy. Finally, Rijneveld talks about the D-ALBA trial, and using blinatumomab in combination with other drugs.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content